Early Clinical Study of Allogenic CD19-CAR-NK Cells (JD001) in the Treatment of Refractory or Relapsed(r/r) B-cell Hematologic Malignancies.

Adrenal Cortex Hormones, Alkylating Agents, Antigen Receptors, Antigens, Antimetabolites, Antineoplastics, B-Cell Lymphoma, B-Cell Receptors, B-Lymphocyte Antigens, Biological Factors, Blood Proteins, CD Antigens, CD19 Antigens, Cancer, Cardiology, Cardiovascular, Cardiovascular Research, Central Nervous System Diseases and Conditions, Central Nervous System Diseases and Conditions - Cerebrovascular Disease, Cerebrovascular Diseases and Conditions, Chemotherapy, Clinical Research, Clinical Trials and Studies, Cyclophosphamide Therapy, Cytapheresis, Drugs and Therapies, Etoposide Therapy, Fludarabine Therapy, Gender Health, Gender and Health, Glucocorticoids, Health and Medicine, Hematology, Immunoglobulins, Immunologic Receptors, Immunology, Immunoproliferative Disorders, Leukapheresis, Leukemia, Lymphatic Diseases and Conditions, Lymphoma, Lymphoproliferative Disorders, Membrane Proteins, Mitotic Inhibitors, Oncology, Pharmaceuticals, Proteins, Women's Health, Leukocyte Reduction Procedures. [Extracted from the article]

Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)